News Author: Jen Smith Publish date: January 31, 2017
SAN FRANCISCO—The phase 3 ALCANZA trial is the first to convincingly demonstrate that a new systemic agent can be more effective than standard o...
News Author: Jen Smith Publish date: December 31, 2016
SAN DIEGO—Neither a 2-drug combination nor a 3-drug combination is superior to 7+3 chemotherapy in younger patients with previously untreated ac...
News Author: Jen Smith Publish date: December 20, 2016
Photo courtesy of CDC
SAN DIEGO—Results from the ARETA trial suggest patients with essential thrombocythemia (ET) can benefit from early treatment ...
News Author: Jen Smith Publish date: December 15, 2016
Photo by Chad McNeeley SAN DIEGO—New research may help inform the management of patients with chronic myeloid leukemia (CML), according to a speake...
News Author: Jen Smith Publish date: December 13, 2016
Photo from UAB Hospital
SAN DIEGO—Results of the phase 3 TRIST study support the use of a restrictive red blood cell (RBC) transfusion strategy in ...
News Author: Jen Smith Publish date: December 12, 2016
Photo by Zak Hubbard SAN DIEGO—Results of the PROUD-PV trial suggest ropeginterferon alfa-2b is safer than hydroxyurea (HU) for patients with polyc...
News Author: Jen Smith Publish date: December 10, 2016
acute myeloid leukemia
SAN DIEGO—A next-generation DNA hypomethylating agent has demonstrated clinical activity and an acceptable safety profile in...
News Author: Jen Smith Publish date: December 9, 2016
© Todd Buchanan 2016
SAN DIEGO—The oral BCL-2 inhibitor venetoclax can produce high objective response rates (ORRs) in chronic lymphocytic leukemia...
News Author: Jen Smith Publish date: December 8, 2016
Photo courtesy of NIH
SAN DIEGO—Results of a phase 2 study suggest an oral mouth rinse formulation of the steroid clobetasol could provide short-te...
News Author: Jen Smith Publish date: December 8, 2016
ASH Annual Meeting SAN DIEGO—When patients with chronic lymphocytic leukemia (CLL) cannot tolerate one Bruton’s tyrosine kinase (BTK) inhibitor, th...
News Author: Jen Smith Publish date: December 6, 2016
ASH Annual Meeting
SAN DIEGO—Interim results of the phase 3 GALLIUM trial suggest an obinutuzumab-based treatment regimen provides a progression-fr...
News Author: Jen Smith Publish date: June 24, 2016
COPENHAGEN—Results from a pair of phase 2 trials suggest luspatercept can produce erythroid responses and enable transfusion independence in patients ...
News Author: Jen Smith Publish date: June 23, 2016
COPENHAGEN—Results of a large study suggest that stopping treatment with tyrosine kinase inhibitors (TKIs) can be safe for patients with chronic myelo...
News Author: Jen Smith Publish date: June 21, 2016
COPENHAGEN—Results of a new study suggest that vitamin K antagonists (VKAs) and non-VKA oral anticoagulants (NOACs) can both confer an increased risk ...
News Author: Jen Smith Publish date: June 20, 2016
Congress of the European
Hematology Association
COPENHAGEN—Results of the phase 3 PATCH trial suggest that platelet transfusions are not beneficia...
